drugset / Trial / NCT00171704
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Phase 3
Completed
263 enrolled
Novartis Pharmaceuticals
Danish Breast Cancer Cooperative Group · collabUniversity of Sheffield · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.
Timeline
- Start
- 2005-04
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |